CagriSema vs Compounded Semaglutide
A side-by-side research comparison of CagriSema and Compounded Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Compounded Semaglutide |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Compounded Semaglutide (503B Pharmacy) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Compounded medication |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Identical to branded semaglutide - a GLP-1 receptor agonist with a fatty acid chain for albumin binding, providing extended half-life. Reduces appetite, slows gastric emptying, and improves insulin sensitivity. |
| Molecular weight | Combination product | 4113.58 Da |
| Half-life | 7 days (both components) | ~7 days |
| Bioavailability | High (SubQ) | ~89% subcutaneous |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 0.25-2.4 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Compounded Semaglutide reported benefits
- Significant weight loss (15-20%)
- Appetite suppression
- Improved glycemic control
- Cardiovascular benefits
- Reduced food noise
Related comparisons
Research and educational reference only. Not medical advice.